Developing Immunologically Inert Adeno-Associated Virus (AAV) Vectors for Gene Therapy: Possibilities and Limitations

E-ISSN： 1873-4316|14|12|1072-1082

ISSN： 1389-2010

Source： Current Pharmaceutical Biotechnology, Vol.14, Iss.12, 2013-01, pp. : 1072-1082

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Generation of Targeted Adeno-Associated Virus (AAV) Vectors for Human Gene Therapy

Current Pharmaceutical Design, Vol. 21, Iss. 22, 2015-01 ,pp. : 3248-3256

Bentham Science Publishers

Access to resources Recommend Favorite

Adeno-Associated Virus (AAV) Vectors in the CNS

Current Gene Therapy, Vol. 5, Iss. 3, 2005-06 ,pp. : 333-338

Bentham Science Publishers

Access to resources Recommend Favorite

Adeno-Associated Virus (AAV) Vectors in the CNS

Current Gene Therapy, Vol. 11, Iss. 3, 2011-06 ,pp. : 181-188

Bentham Science Publishers

Access to resources Recommend Favorite

From Virus Evolution to Vector Revolution: Use of Naturally Occurring Serotypes of Adeno-associated Virus (AAV) as Novel Vectors for Human Gene Therapy

Current Gene Therapy, Vol. 3, Iss. 4, 2003-01 ,pp. : 281-304

Bentham Science Publishers

Access to resources Recommend Favorite

Safety of adeno-associated virus gene therapy vectors: a current evaluation

By Monahan Paul E Jooss Karin Sands Mark S

Expert Opinion on Drug Safety, Vol. 1, Iss. 1, 2002-05 ,pp. : 79-91

Informa Healthcare

Access to resources Recommend Favorite